在 February 10, 2026, 这 美国食品药品管理局 宣布 comprehensive post-market safety reassessment of butylated hydroxyanisole (BHA) used as a 食品添加剂 和 food contact substance in the U.S. food supply. The agency also issued a Request for Information (RFI), inviting industry and stakeholders to submit scientific data and technical information by April 13, 2026. This review affects manufacturers, suppliers, and distributors of foods, and food packaging materials containing BHA.
更新详情
The FDA’s announcement initiates a systematic re-evaluation of BHA’s safety 基于 current scientific evidence, 包括 recent toxicological findings 和 stakeholder input. This action forms part of the FDA’s expanded program to reassess chemical additives used in foods after-market authorization. BHA has been identified as a priority substance due to its continued presence in widely consumed products such as cereals, snack foods, and processed meats.
The review explicitly covers BHA used for direct addition to foods as well as its use in food contact materials, including packaging. The FDA noted that products containing BHA, including those marketed to children, may be subject to future regulatory changes, depending on the outcome of the assessment. The agency also indicated that similar reviews are planned for other additives， 包括 butylated hydroxytoluene (BHT) and azodicarbonamide, following the completion of the BHA review.
反馈截止日期
Technical data and scientific information must be submitted by April 13, 2026.
The FDA stated that late or untimely submissions will not be considered as part of its initial safety determination.
为什么重要
This reassessment provides greater 监管透明度 on how the FDA evaluates post-market safety of food additives using updated scientific evidence. It supports alignment with current toxicological standards and reinforces a more data-driven and transparent regulatory process. For industry, the defined submission window helps ensure efficient inclusion of proprietary safety data, while minimizing the risk that decisions are made based solely on public or incomplete information.
这适用于哪些人群
此更新尤其适用于 Regulatory Affairs, Quality Assurance, Food Safety, R&D, 和 Packaging Compliance teams involved in the formulation, approval, or lifecycle management of foods and food contact materials containing BHA.
下一步
Stakeholders should review the full notice, including 91 FR 6227, to understand the 10 specific categories of information requested by the FDA. Cross-functional coordination is recommended to compile toxicological data, usage levels, and exposure information, with sufficient time allocated for internal legal review of confidential business information (CBI) before submission ahead of the April deadline.
As regulatory authorities increasingly revisit legacy approvals using updated science, having structured visibility into evolving safety reviews becomes critical. RegASK supports organizations navigating such reassessments by delivering timely regulatory intelligence, impact analysis, and coordinated workflows, helping teams respond efficiently to RFIs and upcoming regulatory actions.
RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK 提供及时、可预测、可操作的洞察和端到端的自动化，简化合规流程，降低风险，并加速进入 160 多个国家的市场。. 了解更多 或者 立即预订演示。
常见问题解答
What is BHA and why is it being reviewed by the FDA?
BHA is an antioxidant used as a food additive and food contact substance. The FDA is reassessing its safety based on current scientific evidence, including recent toxicological findings and stakeholder input.
Does the FDA review apply to food packaging as well as food ingredients?
Yes. The reassessment covers both direct addition of BHA to foods and its use in food contact materials, such as packaging.
What happens if industry data is not submitted by April 13, 2026?
If data is not submitted by the deadline, the FDA may base its initial safety determination solely on publicly available information, which may be less comprehensive than industry-held data.
How can RegASK help companies respond to the FDA’s BHA reassessment?
RegASK helps teams track FDA safety reviews, assess regulatory impact, coordinate data collection, and manage submission timelines, enabling a more structured and proactive response to RFIs and post-market reassessments.
